Your browser is no longer supported. Please, upgrade your browser.
BIIB Biogen Inc. monthly Stock Chart
BIIB [NASD]
Biogen Inc.
IndexS&P 500 P/E10.63 EPS (ttm)28.24 Insider Own0.10% Shs Outstand179.92M Perf Week0.15%
Market Cap54.02B Forward P/E9.13 EPS next Y32.90 Insider Trans-0.58% Shs Float175.31M Perf Month3.90%
Income5.42B PEG2.06 EPS next Q7.92 Inst Own92.00% Short Float1.91% Perf Quarter30.55%
Sales14.23B P/S3.80 EPS this Y24.50% Inst Trans-1.41% Short Ratio1.47 Perf Half Y31.46%
Book/sh76.06 P/B3.95 EPS next Y-0.50% ROA20.50% Target Price301.32 Perf Year-8.09%
Cash/sh24.66 P/C12.17 EPS next 5Y5.17% ROE40.10% 52W Range215.77 - 344.00 Perf YTD-0.22%
Dividend- P/FCF8.17 EPS past 5Y22.70% ROI23.60% 52W High-12.72% Beta1.10
Dividend %- Quick Ratio1.70 Sales past 5Y14.20% Gross Margin86.00% 52W Low39.15% ATR8.91
Employees7800 Current Ratio1.90 Sales Q/Q4.70% Oper. Margin47.10% RSI (14)64.56 Volatility4.22% 2.89%
OptionableYes Debt/Eq0.43 EPS Q/Q17.30% Profit Margin37.90% Rel Volume0.99 Prev Close299.39
ShortableYes LT Debt/Eq0.32 EarningsJan 21 BMO Payout0.00% Avg Volume2.28M Price300.26
Recom2.70 SMA203.06% SMA5012.20% SMA20020.43% Volume2,261,355 Change0.29%
Dec-02-19Downgrade Robert W. Baird Neutral → Underperform
Nov-12-19Initiated SunTrust Buy $337
Nov-01-19Downgrade Standpoint Research Buy → Hold
Oct-30-19Upgrade Bernstein Mkt Perform → Outperform
Oct-23-19Upgrade SVB Leerink Mkt Perform → Outperform $256 → $350
Oct-23-19Upgrade Guggenheim Neutral → Buy $256 → $365
Oct-23-19Reiterated H.C. Wainwright Buy $300 → $335
Oct-23-19Reiterated BofA/Merrill Underperform $200 → $235
Oct-17-19Resumed BofA/Merrill Underperform $200
Jun-28-19Downgrade Piper Jaffray Overweight → Neutral $280 → $250
Jun-05-19Upgrade Standpoint Research Hold → Buy
May-23-19Resumed Citigroup Neutral
May-23-19Initiated Wedbush Neutral
May-21-19Initiated Credit Suisse Underperform $198
Apr-10-19Resumed Raymond James Mkt Perform
Mar-25-19Reiterated H.C. Wainwright Buy $363 → $300
Mar-22-19Reiterated BMO Capital Markets Market Perform $322 → $250
Mar-22-19Downgrade UBS Buy → Neutral $395 → $242
Mar-22-19Downgrade Morgan Stanley Overweight → Underweight $401 → $210
Mar-22-19Downgrade Canaccord Genuity Buy → Hold $396 → $275
Dec-08-19 09:27AM  Bulls And Bears Of The Week: Facebook, Intel, Netflix, Tesla And More Benzinga
Dec-06-19 04:31PM  Biogen Edges Near Breakout But Will Its Alzheimer's Drug Pass Muster? Investor's Business Daily
03:08PM  Alzheimers expert says more clinical trials are needed for controversial Biogen drug MarketWatch
11:52AM  Biogen CEO on Controversial Alzheimers Drug: There Is Hope Meredith Videos
11:19AM  Risks of Biogen Alzheimers Drug Are Clear, but Its Benefits Are Still Unproven, Says Raymond James Barrons.com
10:58AM  Cassava stock is up on Alzheimer's data MarketWatch
10:22AM  Money Is Moving Back Into Surging Biotech Funds Barrons.com
09:55AM  Biogen Analysts Divided Over Alzheimer's Drug Following CTAD Presentation Benzinga
09:30AM  Biogen Up on New Data on Alzheimer's Candidate Aducanumab Zacks
08:00AM  Is Biogen Stock A Buy After Rocketing On A New Analysis In Alzheimer's? Investor's Business Daily
Dec-05-19 08:50PM  After Biogen's big Alzheimer's drug data reveal, observers remain divided American City Business Journals
07:35PM  Eisai, Partner Biogen Gain as Alzheimers Drug Studies Revived Bloomberg
04:32PM  Astellas-Audentes Deal Likely to Ignite More Acquisitions GuruFocus.com
04:07PM  Biogen Stock Pops: Here's What Happened In Its Alzheimer's Update Investor's Business Daily
04:06PM  Biogen Stock Is Rising After a Presentation at an Alzheimers Conference Barrons.com
02:50PM  Wild Biotech Day Sparks $7.6 Billion Shuffle for Neurology Trio Bloomberg
02:19PM  Biogen stock climbs as investors shrug off analyst skepticism about Alzheimers drug MarketWatch
02:01PM  Biogen's CTAD Presentation On Aducanumab Elicits Mixed Response Benzinga
01:44PM  Biogen Has More Hope Than Data for Alzheimers Drug Bloomberg
12:56PM  The Dow Goes Negative Despite a Glimmer of Hope on Trade Barrons.com
12:22PM  Biogen shares rise on Alzheimer's candidate data MarketWatch
10:08AM  Biotech Stocks Are Making Wild Moves Amid a Deluge of Trial Data Barrons.com
09:51AM  UPDATE 1-Novartis R&D boss says doesn't see big opportunity in oral SMA therapy Reuters
08:51AM  Aurinia's Lupus Candidate Succeeds in Pivotal Study, Stock Up Zacks
08:15AM  Biogen Shares Up After Alzheimer Drug Tests Show No New Concerns TheStreet.com
06:00AM  Biogen to make case to skeptics for its controversial Alzheimer's drug Reuters
02:00AM  OPEC, Huawei, PG&E, Biogen, and a 2020 Recession? - 5 Things You Must Know TheStreet.com
Dec-04-19 10:25AM  Biogen's Lupus Candidate Meets Endpoint in Phase II Study Zacks
10:13AM  Anavex shares rise in advance of Alzheimer's meeting MarketWatch
10:02AM  Biotech Stock Roundup: Pipeline Updates From BIIB, AXSM, CARA, Collaborations & More Zacks
Dec-03-19 11:22AM  Cramer Weighs In On Biogen, Caterpillar And More Benzinga
09:29AM  Biogen's Shares Down on Rating Downgrade by Baird Analyst Zacks
09:26AM  Where to Buy Booming Biotech ETFs Investopedia
07:30AM  Biogen Announces Positive Phase 2 Study Results for Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE) GlobeNewswire
Dec-02-19 04:13PM  Biogen Stock Is Facing A Crucial Test Here's What You Need To Know Investor's Business Daily
01:56PM  Biogen's shares drop on critical view of Alzheimer's data MarketWatch
01:55PM  Biogen's Alzheimer's Drug 'Falls Far Short Of Compelling Argument For Approval,' Baird Says In Downgrade Benzinga
10:25AM  Biogens Alzheimers Drug Wont Get Approved, Analyst Says Barrons.com
09:48AM  Biogen Downgraded by Baird Analyst Over Move to Salvage Alzheimers Drug Bloomberg
06:24AM  Have Insiders Been Buying Biogen Inc. (NASDAQ:BIIB) Shares? Simply Wall St.
Dec-01-19 09:30AM  The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More Benzinga
Nov-28-19 10:24PM  Hedge Funds Warming Up To Biogen Inc. (BIIB) Again Insider Monkey
07:00AM  The 3 Worst-Performing Health Care Stocks of 2019 So Far Barrons.com
Nov-27-19 10:09AM  Biotech Stock Roundup: CBAY Falls, CCXI Gains, Amgen Acquires Otezla & More Zacks
08:52AM  ChemoCentryx Up on Encouraging Rare Disease Candidate Data Zacks
08:24AM  The Zacks Analyst Blog Highlights: Vertex, Biogen, BioMarin and Alexion Zacks
06:52AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
Nov-26-19 06:07AM  4 Big Drug Stocks Ripe for Takeover After NVS-MDCO Deal Zacks
Nov-25-19 04:59PM  Roche's NDA for SMA Drug Risdiplam Gets Priority Review Zacks
02:45PM  Biogen Sees Its Composite Rating Rise To 97 Investor's Business Daily
05:10AM  Roche eyes quick FDA approval in SMA race with Biogen, Novartis Reuters
03:31AM  UPDATE 1-Roche eyes quick FDA approval in SMA race with Biogen, Novartis Reuters
Nov-22-19 09:45AM  Biogen Ends Enrollment in Eye Disorder Study on Gene Therapy Zacks
08:36AM  AstraZeneca Gets FDA Nod for Calquence Line Extension in CLL Zacks
08:28AM  Biotech Stock Funds Just Arent Getting a Break From Outflows Barrons.com
07:30AM  Biogen Presents Data Demonstrating Improved Gastrointestinal Tolerability With VUMERITY (diroximel fumarate) Compared to TECFIDERA® (dimethyl fumarate) GlobeNewswire
Nov-21-19 02:41PM  Biogen, Novartis named in settlement between foundation, federal prosecutors American City Business Journals
11:00AM  Top Health Care Stocks for December 2019 Investopedia
07:30AM  Biogen Announces Enrollment Completion of Global Phase 3 Gene Therapy Study for an Inherited Retinal Disorder GlobeNewswire
Nov-20-19 03:44PM  Charity to pay $4 million to resolve U.S. pharma kickback probe Reuters
03:32PM  Charity to pay $4 million to resolve U.S. pharma kickback probe Reuters
07:15AM  Healthcare ETF (RYH) Hits New 52-Week High Zacks
Nov-19-19 11:29AM  Biogen shares rise on patent resolution with Sawai MarketWatch
10:14AM  4 Big Biotech Stocks Worth Considering Post Q3 Earnings Zacks
Nov-18-19 10:44AM  Top & Flop ETFs Halfway Through Q4 Zacks
Nov-15-19 04:44AM  Market Morning: Alibaba Goes Hong Kong, Uber Dump, Alzheimers Hope, Cannabis Collapse Market Exclusive
Nov-14-19 03:08PM  Biogen shares fall 3% MarketWatch
01:31PM  Healthcare Drives Wall Street: 5 Soaring ETFs & Stocks Zacks
12:01PM  Biogen Sheds $3 Billion in Value on Top Drugs Patent Review Bloomberg
Nov-13-19 03:43PM  Biotech Stock Roundup: SLDB Plunges, CELG Gets FDA Nod for Reblozyl & Other Updates Zacks
12:32PM  6 Undervalued Stocks According to the Peter Lynch Value GuruFocus.com
Nov-12-19 11:37AM  Buy Big Biotech But Not Gilead, Analyst Says Barrons.com
09:43AM  Roche's SMA Drug Meets Primary Endpoint in Pivotal Study Zacks
07:00AM  Alkermes Announces Receipt of $150 Million Milestone Payment from Biogen Related to FDA Approval of VUMERITY PR Newswire
Nov-11-19 09:28AM  4 Biotech Stocks That Could Keep Beating Wall Street Zacks
09:03AM  AbbVie Eyes Approval for Imbruvica+Rituxan in First-Line CLL Zacks
03:23AM  UPDATE 1-Roche sets sights on Novartis, Biogen as SMA trial hits target Reuters
Nov-08-19 02:58PM  The Unloved Biotechnology ETF Rally ETF Trends
08:24AM  Biotech Funds Are Beating the Market, but Investors Are Still Bailing Out Barrons.com
08:00AM  Pharma Sector Tops in October: Best ETFs & Stocks Zacks
Nov-07-19 11:53AM  Biotech Stock On The Radar: Alkermes At A Crossroads Benzinga
Nov-06-19 08:20AM  Biogen ups investment in biosimilars MarketWatch
07:30AM  Biogen to Expand Biosimilars Portfolio and Gain Access to Additional Markets Through New Transaction with Samsung Bioepis GlobeNewswire
Nov-05-19 08:32AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
Nov-04-19 05:05PM  Biotech ETFs in Focus on Impressive Q3 Earnings Results Zacks
04:30PM  Biogen to Host Investor Webcasts from Clinical Trials on Alzheimers Disease (CTAD) Congress on December 5, 2019 GlobeNewswire
02:28PM  Sanofi settles 4-year legal battle over Genzyme drug for $315M American City Business Journals
02:24PM  Chinese Regulators Tentatively Approve Novel Alzheimer's Drug The First Since 2003 Benzinga
01:00PM  Value Biotech ETFs & Stocks to Buy Now Zacks
Nov-01-19 02:16PM  The Good, Bad, and Ugly for Biogen Stock InvestorPlace
11:34AM  Healthcare ETF (IHF) Tops in October: 5 Best Stocks Zacks
06:54AM  How Does Biogen's (NASDAQ:BIIB) P/E Compare To Its Industry, After Its Big Share Price Gain? Simply Wall St.
Oct-31-19 01:57PM  Cramer Makes The Case Why Biogen's Stock Could Double In Value Benzinga
06:52AM  Calculating The Fair Value Of Biogen Inc. (NASDAQ:BIIB) Simply Wall St.
Oct-30-19 10:43AM  Healthcare ETFs Win in October: Here's Why Zacks
10:34AM  Biogens Alzheimers Drug Could Be a Winner. One Analyst Recommends the Bet. Barrons.com
09:13AM  Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts TheStreet.com
08:03AM  UPDATE 2-Small relief for Biogen in MS drug approval Reuters
07:41AM  FDA approves multiple sclerosis drug from Biogen and Alkermes Reuters
07:40AM  Biogen's and Alkermes' Vumerity gets FDA approval for MS; Biogen's stock surges MarketWatch
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kramer RobinVP, Chief Accounting OfficerDec 03Option Exercise0.00840175Dec 05 04:24 PM
Posner Brian SDirectorDec 02Sale292.351,055308,4296,995Dec 03 05:58 PM
Guindo ChirfiEVP Glob. Prod Strat and CommDec 01Option Exercise0.0054302,855Dec 03 05:59 PM
Gregory GingerEVP, Human ResourcesAug 01Option Exercise0.0017902,295Aug 05 04:20 PM
Karp DanielEVP, Corporate DevelopmentJul 02Option Exercise0.001960322Jul 05 04:51 PM
Ehlers Michael DEVP, Research and DevelopmentJun 01Option Exercise0.001,12608,525Jun 04 04:56 PM
Vounatsos MichelChief Executive OfficerMay 02Option Exercise0.001,480022,487May 06 04:20 PM
DENNER ALEXANDER JDirectorMay 02Buy231.2438,0008,787,120643,000May 02 05:06 PM
DENNER ALEXANDER JDirectorMay 01Buy229.4630,0006,883,800605,000May 02 05:06 PM
Vounatsos MichelChief Executive OfficerMay 01Buy231.484,3511,007,16921,007May 02 04:30 PM
DENNER ALEXANDER JDirectorApr 30Buy229.2550,34211,540,904575,000May 02 05:06 PM
PANGIA ROBERT WDirectorMar 18Option Exercise52.226,114319,27324,701Mar 19 04:08 PM
PANGIA ROBERT WDirectorMar 18Sale328.556,1142,008,75518,587Mar 19 04:08 PM
McKenzie PaulEVP Pharmaceutical Oper & TechMar 01Option Exercise0.0056807,488Mar 05 04:17 PM
ALEXANDER SUSAN HEVP Chief Legal Officer & Sec.Feb 22Option Exercise38.518,058310,28536,085Feb 26 05:09 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 22Option Exercise0.001,663011,148Feb 26 05:07 PM
Vounatsos MichelChief Executive OfficerFeb 15Option Exercise0.005,269018,914Feb 20 06:10 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 15Option Exercise0.001,318010,071Feb 20 06:08 PM
McKenzie PaulEVP Pharmaceutical Oper & TechFeb 15Option Exercise0.001,44807,968Feb 20 06:07 PM
Ehlers Michael DEVP, Research and DevelopmentFeb 15Option Exercise0.001,68508,526Feb 20 05:54 PM
ALEXANDER SUSAN HEVP Chief Legal Officer & Sec.Feb 15Option Exercise0.001,685028,776Feb 20 05:53 PM
Vounatsos MichelChief Executive OfficerFeb 12Option Exercise0.006,899016,267Feb 14 06:33 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 12Option Exercise0.004,64309,452Feb 14 06:29 PM
McKenzie PaulEVP Pharmaceutical Oper & TechFeb 12Option Exercise0.003,06207,059Feb 14 06:17 PM
Gregory GingerEVP, Human ResourcesFeb 12Option Exercise0.001,83602,561Feb 14 06:10 PM
Ehlers Michael DEVP, Research and DevelopmentFeb 12Option Exercise0.003,82707,639Feb 14 06:07 PM
ALEXANDER SUSAN HEVP Chief Legal Officer & Sec.Feb 12Option Exercise0.003,268027,710Feb 14 06:04 PM
DENNER ALEXANDER JDirectorFeb 01Buy328.457,0002,299,163524,658Feb 01 04:19 PM
DENNER ALEXANDER JDirectorJan 31Buy330.5225,8008,527,393517,658Feb 01 04:19 PM
DENNER ALEXANDER JDirectorJan 30Buy324.8630,0009,745,851491,858Feb 01 04:19 PM
CAPELLO JEFFREY DEVP & Chief Financial OfficerJan 02Option Exercise0.001,33101,331Jan 04 04:17 PM